Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance.

Diabetes (Impact Factor: 8.47). 06/2005; 54(5):1566-72.
Source: PubMed

ABSTRACT Increases in subclinical inflammation (C-reactive protein [CRP]) and impaired coagulation have been associated with increased obesity and insulin resistance. Only a few small studies have examined the effect of lifestyle changes, such as weight loss, increased physical activity, and insulin-sensitizing intervention on inflammation and coagulation. The Diabetes Prevention Program (DPP) clinical trial studied the effect of an intensive lifestyle intervention or metformin on progression to diabetes relative to placebo in 3,234 adults with impaired glucose tolerance. The effects of these interventions on CRP and fibrinogen at 12 months are examined in this report. Metformin reduced CRP in women compared with the placebo group. In men, the median changes in CRP from baseline to 1 year were -33% in the lifestyle group, -7% in the metformin group, and +5% in the placebo group. In women, the changes in CRP from baseline to follow-up were -29% in the lifestyle group, -14% in the metformin group, and 0% in the placebo group. In the lifestyle group weight loss rather than increased physical activity seems to account for most of the changes in CRP. Only modest reductions (although significant) were seen in fibrinogen levels in the lifestyle group relative to the metformin and placebo group. Lifestyle intervention reduced levels of nontraditional cardiovascular risk factors relative to both placebo and to a lesser degree to metformin.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It is recognized that a chronic low-grade inflammation and an activation of the immune system are involved in the pathogenesis of obesity-related insulin resistance and type 2 diabetes. Systemic inflammatory markers are risk factors for the development of type 2 diabetes and its macrovascular complications. Adipose tissue, liver, muscle and pancreas are themselves sites of inflammation in presence of obesity. An infiltration of macrophages and other immune cells is observed in these tissues associated with a cell population shift from an anti-inflammatory to a pro-inflammatory profile. These cells are crucial for the production of pro-inflammatory cytokines, which act in an autocrine and paracrine manner to interfere with insulin signaling in peripheral tissues or induce β-cell dysfunction and subsequent insulin deficiency. Particularly, the pro-inflammatory interleukin-1β is implicated in the pathogenesis of type 2 diabetes through the activation of the NLRP3 inflammasome. The objectives of this review are to expose recent data supporting the role of the immune system in the pathogenesis of insulin resistance and type 2 diabetes and to examine various mechanisms underlying this relationship. If type 2 diabetes is an inflammatory disease, anti-inflammatory therapies could have a place in prevention and treatment of type 2 diabetes.
    Diabetes research and clinical practice 04/2014; 105(2). DOI:10.1016/j.diabres.2014.04.006 · 2.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The concept that inflammation governs atherosclerosis and its complications has provided a new unifying hypothesis of the links between risk factors and the cellular and molecular alterations that underlie this disease. This new mechanistic insight has already begun to translate into changes in clinical practice. The preponderance of available data supports the predictive power of biomarkers of inflammation such as high-sensitivity C-reactive protein (hsCRP) in broad categories of individuals, both those who are apparently well and those with already-manifest atherosclerotic cardiovascular disease. The demonstrated clinical utility of hsCRP and potentially of other inflammatory biomarkers has engendered intense interest in evaluating their cost-effectiveness as predictive tools beyond conventional risk markers and as goals for therapy. The rapid translation of inflammation biology in cardiovascular disease from the laboratory to the clinic serves as a gratifying example of bench-to-bedside research. Ultimately, the insight that inflammation plays a fundamental role in atherosclerosis may lead to novel therapies that target aspects of the inflammatory process smoldering within the atheroma.
    Journal of the American College of Cardiology 48(9):A33–A46. DOI:10.1016/j.jacc.2006.08.011 · 15.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: More than one-third of women in the United States are obese. This fact is of particular concern given that obesity contributes to increased risk of several diseases that affect women, including cardiovascular disease. Even modest weight loss, however, can prevent and improve cardiovascular risk factors in obese women. Behavioral interventions for the treatment of obesity that aim to produce weight loss via modification of diet and exercise habits appear to be particularly effective in this regard. This article summarizes research on the effects of behaviorally produced weight loss on cardiovascular risk, principal strategies to improve behavioral weight loss outcomes, and key components of successful long-term weight maintenance.
    Current Cardiovascular Risk Reports 05/2009; 3(3):219-225. DOI:10.1007/s12170-009-0034-7

Full-text (2 Sources)

Available from
May 28, 2014